CANADIAN JOURNAL OF CARDIOLOGY, vol.19, no.5, pp.535-541, 2003 (SCI-Expanded)
BACKGROUND: Cardiotoxicity is the main complication of adriamycin (ADR), which is a widely used chemotherapeutic agent.